权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project LIPICARE - Combining nanotechnology, gene editing and CAR-T to create a 'one-shot' cure for cancer

LIPICARE 项目 - 结合纳米技术、基因编辑和 CAR-T 创造一种“一次性”治愈癌症的方法

基本信息

批准号：
10034471
负责人：
金额：
$ 153.66万
依托单位：
NANOVATION THERAPEUTICS UK LTD
依托单位国家：
英国
项目类别：
Collaborative R&D
财政年份：
2023
资助国家：
英国
起止时间：
2023 至无数据
项目状态：
未结题

来源：
https://gtr.ukri.org/projects?ref=10034471
关键词：
Project LIPICARE Combining nanotechnology gene

项目摘要

LIPICARE is a bold and ambitious project conceived by a consortium of the UK's leading scientists in the field of gene and cancer therapy. We aim to combine advances in nanotechnology, cell therapy and gene editing to create a one-shot cure for cancer.Chimeric Antigen Receptor -- T cell (CAR-T) cancer immunotherapy involves genetically manipulating immune cells to attack cancers and represents a global market worth 20 billion dollars. Approved CAR-T products are all ex vivo therapies involving the complex and expensive process of manipulating cells in a lab and re-introducing them into a patient. One challenge, above all else, has prevented widespread adoption of this revolutionary technology, namely the inability to deliver therapeutic nucleic acids safely and effectively to the specific cells in the body.The COVID 19 pandemic has emphatically shown the lipid nanoparticle (LNP) mRNA delivery platforms are safe and effective in humans. Moreover, these LNP-mRNA vaccines can be manufactured for as little as £15 a dose. The next step is to guide these gene delivery technologies to specific cells in the body. This project will break down this current delivery barrier by creating T-cell specific LNP-nucleic acid delivery technologies to create CAR-T cells in vivo resulting in a cost-effective, accessible treatment for cancer -- Project LIPICARE.

LIPICARE是一个大胆而雄心勃勃的项目，由英国基因和癌症治疗领域的领先科学家组成的财团构想。我们的目标是将纳米技术、细胞治疗和基因编辑的进步联合收割机结合起来，创造一种一次性治愈癌症的方法。嵌合抗原受体- T细胞（CAR-T）癌症免疫疗法涉及遗传操纵免疫细胞来攻击癌症，代表着价值200亿美元的全球市场。批准的CAR-T产品都是离体疗法，涉及在实验室中操作细胞并将其重新引入患者的复杂而昂贵的过程。最重要的是，一个挑战阻碍了这项革命性技术的广泛采用，即无法将治疗性核酸安全有效地递送到体内的特定细胞。COVID 19大流行强调了脂质纳米颗粒（LNP）mRNA递送平台在人类中的安全性和有效性。此外，这些LNP-mRNA疫苗的生产成本低至15英镑一剂。下一步是将这些基因递送技术引导到体内的特定细胞。该项目将通过创建T细胞特异性LNP核酸递送技术来打破目前的递送障碍，以在体内创建CAR-T细胞，从而产生具有成本效益的、可获得的癌症治疗--LIPICARE项目。